IL2 and melanoma: To determine whether the cellular transportation of BG34-200 compounds to TDLNs was accompanied by T-cell activation, we collected TdLNs from PBS- and BG34-200-treated mice, cultured cells in the presence of CD3/CD28 activation beads and recombinant IL-2 and examined the CD8+ T-cell proliferation in response to melanoma H2-Db restricted gp10025−33 peptide and examined the cell expansion and proliferation (Figure 5D).